Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
The FDA tentatively approved a generic injectable version for use in specified lower-income countries under an existing U.S. government program.
TL;DR
- The FDA gave tentative approval to Dr. Reddy's generic injectable lenacapavir for HIV prevention, according to the Associated Press and STAT.
- The approval was made under a U.S. government program for HIV-related medicines supplied to other countries, rather than as a general U.S. market authorization.
- Dr. Reddy's, Unitaid, the Clinton Health Access Initiative and Wits RHI said the generic could become available in some countries within weeks, subject to local processes.
The Associated Press and STAT reported that the FDA tentatively approved a generic injectable version of lenacapavir developed by Dr. Reddy's Laboratories. The medicine is used as a long-acting option for HIV prevention. [1] [2]
AP said the FDA acted under a longstanding U.S. government practice intended to ensure the quality of HIV-related medicines supplied to other countries. The tentative approval is not broad U.S. commercial approval. [1] [2]
The Clinton Health Access Initiative said the approval supports a planned pathway to make the generic available in 120 countries. AP reported that availability could begin in some places within weeks, while countries with their own approval requirements may take longer. [1] [2] [3]
The reporting establishes the regulatory step and access plan, not how many people will receive the drug or the final timing in each country. Local regulatory decisions, supply and implementation remain to be determined. [1] [2]
Why it matters
The FDA action could widen the set of countries with a route to lower-cost access to a long-acting HIV-prevention medicine. The tentative approval and intended distribution pathway are documented; country-level availability and uptake are not yet known.
Editor's note
This is a regulatory and access story, not medical advice. The FDA action is tentative and tied to a U.S. government supply program for other countries.